Health Equity and Risk Communication in Pharmacogenomics

药物基因组学中的健康公平和风险沟通

基本信息

  • 批准号:
    10264062
  • 负责人:
  • 金额:
    $ 16.73万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-15 至 2025-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT The purpose of this Mentored Clinical Scientist Research Career Development Award (K08) is to provide Dr. Loren Saulsberry with a mentored training experience designed to lead to an independent academic career in genomic medicine. Dr. Saulsberry has a PhD in Health Policy. She is currently an Assistant Professor in the Department of Health Sciences at The University of Chicago. Her long-term career goal is to lead a research program that evaluates and guides the implementation of pharmacogenomics (PGx) into clinical practice in a manner that advances health equity in genomic medicine. The proposed work leverages skills she developed through prior training and research and will form the basis for a successful R01 proposal. The career development plan includes didactic and experiential learning in pharmacogenomics; developing research skills in implementation science; acquiring leadership skills for directing interdisciplinary, implementation research teams; and maximizing professional development through a series of objectives. Dr. Saulsberry will also attend seminars, journal clubs, laboratory and research meetings, grant-writing workshops, and present at national meetings, which will all provide additional opportunities to develop and strengthen skills. The mentorship team for the proposed interdisciplinary project covers the full translational cycle of PGx research to ensure training and preparation for independence is comprehensive, incorporating knowledge of each stage of translation from research to practice. The proposed studies build on Dr. Saulsberry's prior work in health disparities and chronic illness; it investigates communication processes essential to PGx implementation, providing a foundation for future studies that evolve approaches for delivering PGx care to patients at risk for health disparities. Aim 1 investigates the inter-ethnic disparities in the use of prescription drugs with evidence-based PGx guidelines and assesses the potential impact of PGx testing on minority populations based on a nationally representative dataset on health care utilization. Aim 2 determines the views of patient-provider pairs on PGx risk communication through interviews/focus groups and examines inter-ethnic variation between patients' risk communication preferences. Aim 3 uses a survey experiment to evaluate the influence of PGx risk information on inter-ethnic patient beliefs and preferences for the clinical use of PGx. This proposal responds to the urgent need to discover methods of tailoring PGx implementation to the expectations and needs of ethnically diverse populations so as to not widen health disparities. The K08 award will lead to Dr. Saulsberry's transition to an independent career in genomic medicine focused on designing and adapting PGx implementation that is minority-centered.
项目总结/摘要 这个指导临床科学家研究职业发展奖(K 08)的目的是提供博士。 洛伦Saulsberry与指导培训经验,旨在导致一个独立的学术生涯, 基因组医学Saulsberry博士拥有卫生政策博士学位。她目前是一个助理教授在 芝加哥大学健康科学系。她的长期职业目标是领导一项研究 该计划评估和指导药物基因组学(PGx)在临床实践中的实施, 促进基因组医学健康公平的方式。拟议的工作利用了她开发的技能 通过事先的培训和研究,并将形成一个成功的R 01提案的基础。职业 发展计划包括药物基因组学的教学和经验学习;发展研究技能 在实施科学;获得领导技能,指导跨学科,实施研究 团队;通过一系列目标最大限度地提高专业发展。Saulsberry博士也将出席 研讨会,期刊俱乐部,实验室和研究会议,赠款写作讲习班,并出席国家 这些会议都将为发展和加强技能提供更多机会。导师团队 拟议的跨学科项目涵盖了PGx研究的整个转化周期,以确保培训 和准备独立是全面的,包括从翻译的每个阶段的知识, 从研究到实践。拟议的研究建立在Saulsberry博士先前在健康差异和慢性疾病方面的工作基础上。 疾病;它调查了PGx实施所必需的沟通过程,为 未来的研究,发展的方法提供PGx护理的患者在健康的差异风险。要求1 采用循证PGx指南调查处方药使用的种族间差异 并根据全国代表性评估PGx检测对少数群体的潜在影响 关于医疗保健利用率的数据集。目标2确定患者-提供者对PGx风险的看法 通过访谈/焦点小组进行沟通,并检查患者风险之间的种族间差异 通信偏好。目的3通过调查实验评估PGx风险信息的影响 不同种族患者对PGx临床使用的信念和偏好。这一建议是对紧急 需要发现定制PGx实施的方法,以满足不同种族的期望和需求 人口,以免扩大健康差距。K 08奖将导致Saulsberry博士过渡到 基因组医学的独立职业生涯专注于设计和调整PGx实施, 少数民族中心。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Loren Saulsberry其他文献

Loren Saulsberry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Loren Saulsberry', 18)}}的其他基金

Health Equity and Risk Communication in Pharmacogenomics
药物基因组学中的健康公平和风险沟通
  • 批准号:
    10474443
  • 财政年份:
    2020
  • 资助金额:
    $ 16.73万
  • 项目类别:
Health Equity and Risk Communication in Pharmacogenomics
药物基因组学中的健康公平和风险沟通
  • 批准号:
    10681471
  • 财政年份:
    2020
  • 资助金额:
    $ 16.73万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.73万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了